DK0891378T3 - Anvendelse af farmaceutisk formulering omfattende et appetitundertrykkende peptid - Google Patents

Anvendelse af farmaceutisk formulering omfattende et appetitundertrykkende peptid

Info

Publication number
DK0891378T3
DK0891378T3 DK97905000T DK97905000T DK0891378T3 DK 0891378 T3 DK0891378 T3 DK 0891378T3 DK 97905000 T DK97905000 T DK 97905000T DK 97905000 T DK97905000 T DK 97905000T DK 0891378 T3 DK0891378 T3 DK 0891378T3
Authority
DK
Denmark
Prior art keywords
peptide
pharmaceutical formulation
appetite suppressant
appetite
absent
Prior art date
Application number
DK97905000T
Other languages
Danish (da)
English (en)
Inventor
Lars Thim
Birgitte Schjellerup Wulff
Martin Edward Judge
Ole Dragsbak Madsen
Jens Juul Holst
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0891378(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of DK0891378T3 publication Critical patent/DK0891378T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK97905000T 1996-03-01 1997-02-27 Anvendelse af farmaceutisk formulering omfattende et appetitundertrykkende peptid DK0891378T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK23196 1996-03-01
DK23096 1996-03-01
PCT/DK1997/000086 WO1997031943A1 (en) 1996-03-01 1997-02-27 Use of a pharmaceutical composition comprising an appetite-suppressing peptide

Publications (1)

Publication Number Publication Date
DK0891378T3 true DK0891378T3 (da) 2003-01-06

Family

ID=26063575

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08103786.3T DK1975177T3 (da) 1996-03-01 1997-02-27 Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
DK97905000T DK0891378T3 (da) 1996-03-01 1997-02-27 Anvendelse af farmaceutisk formulering omfattende et appetitundertrykkende peptid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08103786.3T DK1975177T3 (da) 1996-03-01 1997-02-27 Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf

Country Status (22)

Country Link
EP (4) EP2295453A3 (enExample)
JP (1) JP4064460B2 (enExample)
KR (1) KR100611130B1 (enExample)
CN (1) CN1112367C (enExample)
AT (3) ATE395359T1 (enExample)
AU (1) AU710818B2 (enExample)
BR (1) BR9707807A (enExample)
CA (1) CA2246733C (enExample)
CY (2) CY2619B2 (enExample)
CZ (1) CZ297338B6 (enExample)
DE (3) DE69717092T2 (enExample)
DK (2) DK1975177T3 (enExample)
ES (3) ES2187756T3 (enExample)
FR (1) FR13C0009I2 (enExample)
HU (1) HU229234B1 (enExample)
IL (1) IL125805A0 (enExample)
NO (2) NO323043B1 (enExample)
PL (1) PL187095B1 (enExample)
PT (1) PT1975177E (enExample)
RU (1) RU2197261C2 (enExample)
UA (1) UA70283C2 (enExample)
WO (1) WO1997031943A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
JP4064460B2 (ja) * 1996-03-01 2008-03-19 ノボ ノルディスク アクティーゼルスカブ 食欲抑制性ペプチドを含む医薬組成物の用途
CN1268640C (zh) 1996-04-12 2006-08-09 1149336安大略公司 胰高血糖素样肽－2的类似物
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0941114B1 (en) * 1996-11-12 2005-02-23 Novo Nordisk A/S Use of glp-1 peptides
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
ATE273996T1 (de) * 1997-09-12 2004-09-15 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
DE69942307D1 (de) * 1998-02-27 2010-06-10 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
JP2002504527A (ja) * 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
AU3087599A (en) * 1998-03-19 1999-10-11 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
ATE396738T1 (de) * 2000-09-18 2008-06-15 Sanos Bioscience As Verwendung von glp-2-peptiden
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
ATE416784T1 (de) 2000-12-01 2008-12-15 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ATE502665T1 (de) 2003-02-04 2011-04-15 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
CA2552043A1 (en) 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
HRP20110831T1 (hr) * 2004-04-15 2012-01-31 Alkermes Pharma Ireland Limited Oblik za produljeno oslobađanje na bazi polimera
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101171262B (zh) 2005-05-04 2012-06-27 西兰制药公司 胰高血糖素样肽-2(glp-2)类似物
ES2397289T3 (es) 2005-09-22 2013-03-06 Biocompatibles Uk Ltd. Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
NZ576260A (en) 2006-11-08 2012-04-27 Zealand Pharma As GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
WO2009021293A1 (en) * 2007-08-16 2009-02-19 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CA3043151A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
EP4424362A3 (en) 2017-06-16 2024-11-27 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
US20220204553A1 (en) * 2019-05-06 2022-06-30 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
HU206897B (en) 1985-10-25 1993-01-28 Zymogenetics Inc Process for utilizing bar-1 gen for selecting strange proteins
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
DE3856247T2 (de) 1987-07-24 1999-04-29 Chiron Corp., Emeryville, Calif. Züchtung von insektenzellen mit airlift-reaktoren
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO1990005783A1 (en) 1988-11-18 1990-05-31 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
JP4064460B2 (ja) * 1996-03-01 2008-03-19 ノボ ノルディスク アクティーゼルスカブ 食欲抑制性ペプチドを含む医薬組成物の用途

Also Published As

Publication number Publication date
DE69717092T2 (de) 2003-07-24
FR13C0009I1 (enExample) 2013-03-22
JP4064460B2 (ja) 2008-03-19
CA2246733C (en) 2010-07-20
PT1975177E (pt) 2011-07-26
AU1871597A (en) 1997-09-16
DE69717092D1 (de) 2002-12-19
AU710818B2 (en) 1999-09-30
HU229234B1 (en) 2013-09-30
DE69738695D1 (de) 2008-06-26
ES2306685T3 (es) 2008-11-16
DE69740176D1 (de) 2011-05-26
EP0891378A1 (en) 1999-01-20
EP0891378B1 (en) 2002-11-13
NO984005L (no) 1998-08-31
CY2013008I2 (el) 2015-08-05
ES2364705T3 (es) 2011-09-12
HUP9902670A3 (en) 2000-02-28
NO2013006I2 (enExample) 2013-03-12
PL187095B1 (pl) 2004-05-31
PL328732A1 (en) 1999-02-15
ATE395359T1 (de) 2008-05-15
NO984005D0 (no) 1998-08-31
ES2187756T3 (es) 2003-06-16
EP1231218A3 (en) 2002-10-30
CZ297338B6 (cs) 2006-11-15
EP2295453A2 (en) 2011-03-16
UA70283C2 (en) 2004-10-15
IL125805A0 (en) 1999-04-11
CY2619B2 (enExample) 2013-03-13
CN1215405A (zh) 1999-04-28
FR13C0009I2 (fr) 2013-08-16
CN1112367C (zh) 2003-06-25
KR19990087439A (ko) 1999-12-27
EP2295453A3 (en) 2011-03-30
WO1997031943A1 (en) 1997-09-04
RU2197261C2 (ru) 2003-01-27
EP1975177A1 (en) 2008-10-01
JP2000505460A (ja) 2000-05-09
CZ273698A3 (cs) 1998-12-16
NO2013006I1 (no) 2013-04-02
CY2013008I1 (el) 2015-08-05
ATE505485T1 (de) 2011-04-15
EP1231218A2 (en) 2002-08-14
BR9707807A (pt) 1999-07-27
DK1975177T3 (da) 2011-07-25
EP1975177B1 (en) 2011-04-13
NO323043B1 (no) 2006-12-27
CA2246733A1 (en) 1997-09-04
ATE227737T1 (de) 2002-11-15
KR100611130B1 (ko) 2006-11-30
EP1231218B1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
DK0891378T3 (da) Anvendelse af farmaceutisk formulering omfattende et appetitundertrykkende peptid
DK1094834T3 (da) Farmaceutisk sammensætning til behandling af funktionel dybspepsi og/eller irritabel tarmsyndrom samt ny anvendelse deraf
EP1529534A3 (en) Use of GLP-1 peptides
NO992557D0 (no) Bruk av GLP-1-analoger og derivater administrert perifert i regulering av fedme
DK1171465T3 (da) Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
DK0966297T3 (da) Regulering af gastroinstestinal motilitet
DK1918298T3 (da) Peptid
WO1999012561A3 (en) FRACTURE HEALING USING PTHrP ANALOGS
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
NO982935D0 (no) Hyaluronsyre reseptor bindende middel og anvendelse derav
ATE305478T1 (de) Topoisomerase-ii inhibitoren